Physician profile
Thomas Freund
NPI 1093700221
$2,048.02
in general payments reported to CMS, 2019-2025
21 companies · $93.81 in 2025
The $93.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $126 · 2021: $195 · 2022: $85.27 · 2023: $564 · 2024: $707 · 2025: $93.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $511.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $291.65 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $277.97 | 2019-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $113.15 | 2022-2024 | Verquvo, Capvaxive |
| Novo Nordisk INC | $106.43 | 2023-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $97.71 | 2023-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.63 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $91.22 | 2023-2025 | |
| Lilly USA, LLC | $74.65 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $63.98 | 2023-2024 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $58.47 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $47.94 | 2020-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $45.59 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $33.00 | 2024 | |
| Exact Sciences Corporation | $22.83 | 2024 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.82 | 2021 | |
| Glaxosmithkline, LLC. | $20.93 | 2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.67 | 2024 | Trulance, Xifaxan |
| Boston Scientific Corporation | $18.51 | 2023 | Watchman Access System |
| Preventice Services, LLC | $17.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Freund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.